LY6D

Across TCGA pan-cancer cohorts, LY6D RNA is linked to patient survival in 22 of 34 cancer types, making it the most broadly survival-associated LY6D data layer compared with 3 for mutation status and 5 for mass-spec protein.

The strongest signal is observed in pancreatic adenocarcinoma (PAAD), where higher LY6D RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LY6D expression acts as an unfavorable survival marker, although some lineages such as ACC and LGG show a favorable association.

PAAD, UVM, and ACC are the cancer types where LY6D RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PAAD	OS	Tertile	All	0.455	0.739	<.001	86	view →
UVM	DFS	Tertile	II,III,IV	0.280	0.630	<.001	81	view →
ACC	OS	Median	II,III,IV	0.890	0.636	<.001	74	view →
SKCM	OS	Tertile	All	0.687	0.858	<.001	59	view →
KIRC	OS	Median	II,III,IV	0.431	0.624	.001	59	view →
MESO	OS	Quartile	III,IV	0.397	0.633	.008	29	view →
OV	OS	Tertile	All	0.784	0.881	.013	28	view →
KIRP	DFS	Median	All	0.584	0.905	<.001	27	view →
LGG	DFS	Median	All	0.876	0.799	.008	24	view →
SCLC	OS	Median	III,IV	0.763	0.442	.008	24	view →
THYM	DFS	Quartile	III,IV	0.674	1.000	.019	20	view →
COAD	DFS	Quartile	IV	0.342	0.681	.003	18	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 22 lineages.

LY6D–PAAD (OS)

Open the PAAD breakdown →